BlackRock Health Sciences Term Trust (NYSE:BMEZ) Declares Monthly Dividend of $0.11

BlackRock Health Sciences Term Trust (NYSE:BMEZ) declared a monthly dividend on Friday, June 5th. Investors of record on Wednesday, July 15th will be paid a dividend of 0.11 per share on Friday, July 31st. This represents a c) dividend on an annualized basis and a yield of 8.5%. The ex-dividend date is Wednesday, July 15th.

BlackRock Health Sciences Term Trust Price Performance

NYSE BMEZ opened at $15.46 on Monday. The stock’s fifty day moving average is $14.60 and its two-hundred day moving average is $14.72. BlackRock Health Sciences Term Trust has a fifty-two week low of $13.67 and a fifty-two week high of $15.80.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BMEZ. Wolverine Asset Management LLC increased its position in BlackRock Health Sciences Term Trust by 78.8% during the fourth quarter. Wolverine Asset Management LLC now owns 401,511 shares of the company’s stock worth $6,043,000 after purchasing an additional 176,993 shares during the last quarter. Indivisible Partners purchased a new position in BlackRock Health Sciences Term Trust during the fourth quarter worth about $820,000. City of London Investment Management Co. Ltd. acquired a new position in BlackRock Health Sciences Term Trust in the 3rd quarter valued at about $1,068,000. Kestra Advisory Services LLC acquired a new position in BlackRock Health Sciences Term Trust in the 4th quarter valued at about $26,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of BlackRock Health Sciences Term Trust in the 1st quarter valued at approximately $35,000.

BlackRock Health Sciences Term Trust Company Profile

BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.

The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services.